Back to Stocks

REFI

Chicago Atlantic Real Estate Finance, Inc.
7 filings tracked
financialsasset managementMICRO (<$300M)

Company Intelligence Hub

Filing history, signal momentum, and bull/bear evolution

Chronological Filing Evolution (Click to filter / toggle)

Thesis (Bull Case Evolution)

Chicago Atlantic Real Estate Finance (REFI) continues to demonstrate the strength of its specialized lending model, operating at the intersection of commercial real estate and the evolving cannabis sector.…

Bullish Outlook

Antithesis (Bear Case / Structural Risks)

Despite the optimistic narrative, REFI's quarterly results reveal mounting credit stress and deteriorating asset quality. The company's current expected credit loss (CECL) reserve surged to $8.68 million, a significant increase that reflects growing anxiety over high-risk loans.…

Risk Factors

Read the full bull/bear analysis

You are reading the free preview. Start a free trial to unlock the complete bull & bear analysis for every REFI filing.

Start Free Trial

Synthesis (Verdict & Resolution)

The Q1 2026 filing presents a company in a delicate transition, balancing high-yield returns against escalating credit risks. While REFI has successfully maintained its dividend and reported positive net income, the divergence between GAAP net income and operating cash flow suggests a reliance on non-cash accruals and revolving credit draws to sustain distributions. The restoration of the $29 million 'Judgment Loan' to accrual status is a positive sign, but the emergence of new non-accrual loans indicates that credit volatility remains a constant feature of the cannabis-finance niche. Ultimately, the investment case for REFI now hinges on the speed and scope of federal rescheduling. If the DEA's move toward Schedule III translates into tangible liquidity for borrowers, REFI could see a broad-based improvement in credit quality. However, until that catalyst materializes, investors must weigh the attractive current yield against a backdrop of increasing loan loss provisions and a concentrated portfolio that leaves little room for underwriting error.

Selected Quarter

Core Takeaway

REFI is maintaining its dividend payout through strong yields, but a sharp increase in CECL reserves and falling operating cash flow suggest deteriorating borrower health.

Investor Lens

The trade-off is between an attractive current yield and the risk of a dividend cut if credit losses accelerate faster than regulatory relief.

Watch Next

The June 29, 2026 DEA hearing regarding adult-use cannabis rescheduling.

View Full SEC Report

Signal Momentum Chart

Quarterly net bull/bear signal ratio. Click nodes to select a quarter.

BULLISH (+1.0)NEUTRAL (0.0)BEARISH (-1.0)-0.12Q2 '26 (10-Q)

Signal Timeline

Active Filters:Quarter: Q2 '26 (10-Q)
bearishMay 7

Weighted average YTM declined from 16.9% to 15.8%.

margin compression
60%
bearishMay 7

Net income fell 52% year-over-year due to increased credit loss provisions.

earnings miss
70%
bullishMay 7

DEA reclassification of medical cannabis to Schedule III provides potential tax relief for borrowers.

regulatory action
80%
neutralMay 7

Maintained quarterly dividend of $0.47 despite falling operating cash flow.

dividend change
20%
bearishMay 7

Weighted average YTM declined from 16.9% to 15.8%.

margin compression
60%
bearishMay 7

Net income fell 52% year-over-year due to increased credit loss provisions.

earnings miss
70%
bullishMay 7

DEA reclassification of medical cannabis to Schedule III provides potential tax relief for borrowers.

regulatory action
80%
neutralMay 7

Maintained quarterly dividend of $0.47 despite falling operating cash flow.

dividend change
20%
bearishMay 7

Weighted average YTM declined from 16.9% to 15.8%.

margin compression
60%
bearishMay 7

Net income fell 52% year-over-year due to increased credit loss provisions.

earnings miss
70%
bullishMay 7

DEA reclassification of medical cannabis to Schedule III provides potential tax relief for borrowers.

regulatory action
80%
neutralMay 7

Maintained quarterly dividend of $0.47 despite falling operating cash flow.

dividend change
20%
bearishMay 7

Weighted average YTM declined from 16.9% to 15.8%.

margin compression
60%
bearishMay 7

Net income fell 52% year-over-year due to increased credit loss provisions.

earnings miss
70%
bullishMay 7

DEA reclassification of medical cannabis to Schedule III provides potential tax relief for borrowers.

regulatory action
80%
neutralMay 7

Maintained quarterly dividend of $0.47 despite falling operating cash flow.

dividend change
20%
bearishMay 7

Weighted average YTM declined from 16.9% to 15.8%.

margin compression
60%
bearishMay 7

Net income fell 52% year-over-year due to increased credit loss provisions.

earnings miss
70%
bullishMay 7

DEA reclassification of medical cannabis to Schedule III provides potential tax relief for borrowers.

regulatory action
80%
neutralMay 7

Maintained quarterly dividend of $0.47 despite falling operating cash flow.

dividend change
20%
bearishMay 7

Weighted average YTM declined from 16.9% to 15.8%.

margin compression
60%
bearishMay 7

Net income fell 52% year-over-year due to increased credit loss provisions.

earnings miss
70%
bullishMay 7

DEA reclassification of medical cannabis to Schedule III provides potential tax relief for borrowers.

regulatory action
80%
neutralMay 7

Maintained quarterly dividend of $0.47 despite falling operating cash flow.

dividend change
20%
bearishMay 7

Weighted average YTM declined from 16.9% to 15.8%.

margin compression
60%
bearishMay 7

Net income fell 52% year-over-year due to increased credit loss provisions.

earnings miss
70%
bullishMay 7

DEA reclassification of medical cannabis to Schedule III provides potential tax relief for borrowers.

regulatory action
80%
neutralMay 7

Maintained quarterly dividend of $0.47 despite falling operating cash flow.

dividend change
20%

Filing History

10-QMay 7, 2026
Expand Sequence

The Q1 2026 filing presents a company in a delicate transition, balancing high-yield returns against escalating credit risks. While REFI has successfully maintained its dividend and reported positive net income, the divergence between GAAP net income and operating cash flow suggests a reliance on non-cash accruals and revolving credit draws to sustain distributions. The restoration of the $29 million 'Judgment Loan' to accrual status is a positive sign, but the emergence of new non-accrual loans indicates that credit volatility remains a constant feature of the cannabis-finance niche. Ultimately, the investment case for REFI now hinges on the speed and scope of federal rescheduling. If the DEA's move toward Schedule III translates into tangible liquidity for borrowers, REFI could see a broad-based improvement in credit quality. However, until that catalyst materializes, investors must weigh the attractive current yield against a backdrop of increasing loan loss provisions and a concentrated portfolio that leaves little room for underwriting error.

Disclaimer: The synthesis provided is generated by AI models and should not be construed as investment advice. Analysis is based solely on regulatory data present at the time of publication. Consult a financial advisor for specific investment strategies.